This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60.
A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceuticalcompanies that will be testifying before Sen. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Bernie Sanders’ HELP Committee today. Read the rest…
The 340B DrugPricing Program has long been a contentious issue for pharma. Either way, reforms to the 340B program, which was created by Congress in 1992 and requires pharmaceuticalcompanies to provide outpatient drug discounts to safety net hospitals, could be on the table.
… Four months ago, a small pharmaceuticalscompany bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150% , STAT says. European pharmaceutical bosses have called on the European Union to increase drugprices toward the much higher levels paid by the U.S.,
Editors picks George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. 4, 2024 Permission granted by Bristol Myers Squibb Deep Dive // Brain drug revival Psychiatry drugs finally have pharma’s attention.
For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceuticalcompanies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing.
Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Just 9% came from the private sector, such as pharmaceuticalcompanies. billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022.
Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drugprices , STAT tells us.
Sit back and relax, while the article unfolds before you, the magic model that is certain to revamp your company Achieving economic sustenance and ensuring smooth sailing even in unfavorable situations are two common dreams that every pharmaceuticalcompany shares.
This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. Based on this ruling, 505(b)(2) drugs that are not therapeutically interchangeable should be considered sole-source drugs.
Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Especially, women tend to have more distrust in pharmaceuticalcompanies.
Both Sandoz and Novartis are internationally renowned pharma companies, with a combined 34 production facilities worldwide. These highlight the parent company’s focus on innovative and high-value drug development. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceuticalcompanies. As a result, the FTSE 350 Pharmaceuticals & Biotech index hit all-time highs in May. COVID-19 sparks change. Two key trends underpin the sector’s resurgence.
The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US. billion between Dec 31, 2021 and Dec 31, 2022, owing to expansion in its vaccine and oncology portfolio.
It goes without saying that if pharmaceuticalcompanies are not profitable, they will not survive. Nowhere has this need for healthy companies been more apparent than during the current global coronavirus pandemic, with multiple manufacturers making COVID-19 vaccines rapidly available to the public. The Big Misconception.
and outperformed maternal vaccines in public health programs. Vaccines to treat RSV normally start in early fall, and having these additional shipments in advance is expected to give healthcare providers (HCPs) an additional assurance and confidence. Sanofi, AstraZeneca Launch Program to Mitigate Future RSV Vaccine Shortages.
See you soon… The Trump administration is pushing pharmaceuticalcompanies to begin negotiations to bring their drugprices in line with what other countries pay — usually far less than Americans , STAT tells us. Two new vaccine advisers tapped by U.S. Kennedy Jr.
By Ned Pagliarulo • June 4, 2025 George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. You can unsubscribe at anytime. By Jonathan Gardner • Sept. By Jonathan Gardner • Sept. TechTarget, Inc.s
The American Hospital Association has warned that increased costs and delays in sourcing critical drugs could lead to shortages of essential medicines, including antibiotics, oncology treatments, and cardiovascular drugs. Generic drug manufacturers, which operate on slim profit margins, are likely to be most affected.
Major pharmaceuticalcompanies including Eli Lilly, Pfizer, and Merck are ramping up manufacturing investments in the US to navigate the evolving trade tariffs and capitalise on domestic tax incentives.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. Go deeper with GlobalData Reports United States of America (USA) DrugPricing and Reimbursement Lands.
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80
Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.s registered office is 275 Grove St.
We don’t believe there will be draconian price cuts, for the same reason. The Biden administration could put additional scrutiny on drugprices, but more drastic measures, such as allowing Medicare to negotiate with pharma companies directly, are still unlikely.”. ” Science first.
In addition to the climate provisions, however, the bill has a significant effect on prescription drugprices, and according to reports neither Manchin nor Sinema is objecting to these provisions, which are similar but not identical to the ones in the Build Back Better plan which previously passed in the House of Representatives.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content